AKR1B1 and colonic neoplasm: Many research groups have predicted the inhibitory effect of various classes of heterocyclic compounds on the other isoforms of aldose reductase that are involved in diabetes [19,20] and cardiac complications [21,22], i.e., ALR-1 and ALR-2, but none of them have been discussed against the selected targeted proteins, i.e., AKR1B1 and AKR1B10, which are specifically involved in colon cancer.